Astellas Pharma US, Inc., is the U.S. affiliate of Astellas Pharma Inc., a R&D-driven global pharmaceutical company. At Astellas, we improve lives through innovative and effective medicines. Our dedication to changing tomorrow for patients and our customers fits closely with our strong scientific orientation and focus on the community in which we work and live.

Research Grants 106 show all


$6M
2015

$23.5M
2016

$9.2M
2018

$8.9M
2019

$6M
2020

Publications 1,219 show all

  • 34
    Tacrolimus/pharmacology
  • 33
    Nifedipine/analogs & derivatives
  • 30
    Enzyme Inhibitors/pharmacology
  • 30
    Immunosuppressive Agents/pharmacology
  • 26
    Anti-Bacterial Agents/pharmacology
  • 25
    Pyridines/pharmacology
  • 23
    Indoles/pharmacology
  • 23
    Streptomyces/metabolism
  • 21
    Pyrazoles/pharmacology
  • 20
    Peptides, Cyclic/pharmacology

Patents 20,875show all

  • 5,785
    C07D - Heterocyclic compounds
  • 3,709
    A61K - Preparations for medical, dental, or toilet purposes
  • 955
    C07K - Peptides
  • 854
    C07C - Acyclic or carbocyclic compounds
  • 644
    Y02P - Climate change mitigation technologies in the production or processing of goods
  • 368
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 306
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 279
    C12N - Microorganisms or enzymes
  • 225
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 192
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical Trials 1,975show all

554N/A402Phase 3314Phase 1306Phase 2240Phase 447Other

Contact Information

Chūō
Japan